ES2054688T3 - Moleculas hibridas recombinantes de inmunoglobulina y su uso. - Google Patents

Moleculas hibridas recombinantes de inmunoglobulina y su uso.

Info

Publication number
ES2054688T3
ES2054688T3 ES87310006T ES87310006T ES2054688T3 ES 2054688 T3 ES2054688 T3 ES 2054688T3 ES 87310006 T ES87310006 T ES 87310006T ES 87310006 T ES87310006 T ES 87310006T ES 2054688 T3 ES2054688 T3 ES 2054688T3
Authority
ES
Spain
Prior art keywords
recombinant hybrid
immunoglobulin
hybrid immunoglobulin
hybrid molecules
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87310006T
Other languages
English (en)
Inventor
Edgar Haber
Thomas Quertermous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2054688T3 publication Critical patent/ES2054688T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA MOLECULA DE INMUNOGLOBULINA HIBRIDA RECOMBINANTE, QUE TIENE UN ANTIGENO QUE ENLAZA SITIOS ESPECIFICOS DE FIBRINA, LIGADA A UNA SEGUNDA PROTEINA, QUE CONTIENE LA PARTE ACTIVA DE UN ACTIVADOR PLASMINOGENO. LA INVENCION TAMBIEN SE REFIERE A LA CLONACION Y PRODUCION DE ESTAS MOLECULAS DE INMUNOGLOBULINA HIBRIDAS. ADEMAS, ESTA INVENCION SE REFIERE A UN METODO PARA UTILIZAR ESTAS MOLECULAS DE INMUNOGLOBULINA HIBRIDAS RECOMBINANTES EN PROCEDIMIENTOS DE INMUNODIAGNOSTICO E INMUNOTERAPEUTICOS
ES87310006T 1986-11-12 1987-11-12 Moleculas hibridas recombinantes de inmunoglobulina y su uso. Expired - Lifetime ES2054688T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92958186A 1986-11-12 1986-11-12

Publications (1)

Publication Number Publication Date
ES2054688T3 true ES2054688T3 (es) 1994-08-16

Family

ID=25458094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87310006T Expired - Lifetime ES2054688T3 (es) 1986-11-12 1987-11-12 Moleculas hibridas recombinantes de inmunoglobulina y su uso.

Country Status (7)

Country Link
EP (1) EP0271227B1 (es)
JP (1) JPH02500950A (es)
AT (1) ATE90385T1 (es)
CA (1) CA1339445C (es)
DE (1) DE3786151T2 (es)
ES (1) ES2054688T3 (es)
WO (1) WO1988003559A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5217705A (en) * 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
KR900702017A (ko) * 1988-06-03 1990-12-05 존 로버트 버쉬 혼성 단백질(bybrid proteins)
WO1990002338A1 (en) * 1988-08-19 1990-03-08 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
EP0449879A1 (en) * 1988-11-25 1991-10-09 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
US5316934A (en) * 1989-06-13 1994-05-31 Nippon Soda Co., Ltd. Effective thrombosis mediated by human prourokinase-like polypeptides with increased binding affinity for thrombosis
JP3319594B2 (ja) * 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
AU7766391A (en) * 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5961973A (en) * 1992-03-06 1999-10-05 Crea; Roberto Pathogen-targeted biocatalysts
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
EP0888381A4 (en) * 1995-12-21 2001-10-17 Scripps Research Inst TARGETED THERAPEUTIC AND DIAGNOSTIC AGENTS, METHODS FOR THEIR PRODUCTION AND USE
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2001502895A (ja) * 1996-09-20 2001-03-06 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
US8609615B2 (en) 2008-10-15 2013-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of myotonic dystrophy
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
NZ626620A (en) 2012-01-10 2016-07-29 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
TWI779252B (zh) * 2018-11-21 2022-10-01 免疫功坊股份有限公司 用於治療病理性血栓的多肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0146050B1 (en) * 1983-12-16 1990-07-04 Denis M. Callewaert Site selective plasminogen activator and method of making and using same
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
WO1987005934A1 (en) * 1986-03-28 1987-10-08 Roberto Crea Protein analogues of tissue plasminogen activator

Also Published As

Publication number Publication date
DE3786151T2 (de) 1994-01-13
EP0271227A3 (en) 1989-09-20
WO1988003559A1 (en) 1988-05-19
EP0271227A2 (en) 1988-06-15
JPH02500950A (ja) 1990-04-05
CA1339445C (en) 1997-09-09
DE3786151D1 (de) 1993-07-15
EP0271227B1 (en) 1993-06-09
ATE90385T1 (de) 1993-06-15

Similar Documents

Publication Publication Date Title
ES2054688T3 (es) Moleculas hibridas recombinantes de inmunoglobulina y su uso.
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
PT87138A (pt) Process for the preparation of adn recombinant molecules codin g polypeptide adn segments and of antibody compositions relate d with human tissue factor
ATE174628T1 (de) Expression rekombinanter fusionsproteine in attenuierten bakterien
DE69534872D1 (de) Gereinigte primate clta-8 antigene und verwandte reagenzien
ATE88572T1 (de) Antikoerper gegen polypeptide, die gegen peptide oder proteine mit mindestens teilweise bekannter aminosaeure oder kodierender nukleotidsequenz komplementaer sind und diesbezuegliches aufbauverfahren.
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
EP0355068A3 (en) Recombinant hybrid immunoglobulin molecules and their use
ATE71109T1 (de) Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung.
DE69029540D1 (de) Oxidative Denaturierung von Eiweissanalyten
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE50458T1 (de) Bestimmung von fibrin mit fibrin-spezifischen antikoerpern.
FI93842B (fi) Menetelmä proteiinien renaturoimiseksi
ES2062759T3 (es) Procedimiento de purificacion de polipeptidos recombinantes.
PT816377E (pt) Peptideos que se ligam a protrombina e a trombina
DE3788169D1 (de) Geräte und Verfahren zur Bestimmung der Sequenz von Aminosäuren.
ES2060927T3 (es) Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.
DE68919758D1 (de) Antikörper gegen Fibrin, Immunogen zur Herstellung desselben, Verfahren zur Bestimmung von Fibrin und pharmazeutisches Präparat auf Basis der Antikörper.
EP0276008A3 (en) Fibrin-specific antibody, method for its production and its use
Naguib et al. Purification of Chironex fleckeri venom components using Chironex immunoaffinity chromatography
DE68919553D1 (de) Rekombinantes Treponema hyodysenteriae-Antigen und seine Verwendungen.
DE3855007D1 (de) METHODE ZUR REINIGUNG REKOMBINANTER t-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN
NO161274C (no) Fremgangsm te for fremstilling av immuninterferon.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 271227

Country of ref document: ES